bluebird bio Extends Tender Offer Deadline to May 12, 2025
Deal News | May 02, 2025 | SK Capital
In a recent announcement, Carlyle and SK Capital Partners have extended their offer to acquire bluebird bio, Inc. by ten days. Beacon Merger Sub, Inc., a subsidiary involved in the acquisition, moved the previous deadline from May 2, 2025, to May 12, 2025. The extension provides additional time to meet outstanding conditions, such as acquiring regulatory approvals. As of May 1, 2025, nearly one million shares of bluebird have been tendered. Founded in 2010, bluebird bio is a leader in the gene therapy sector, recognized for receiving FDA approvals for three therapies in less than two years. Carlyle is a global investment firm with $441 billion in assets, while SK Capital focuses on life sciences and specialty materials, managing a $9 billion portfolio. All tender offers and related documents are filed with the SEC and available to investors.
Sectors
- Private Equity
- Biotechnology
- Investment Banking
Geography
- United States – The transaction involves companies and regulatory processes based in the United States.
Industry
- Private Equity – The article covers the involvement of private equity firms, Carlyle and SK Capital Partners, in the acquisition process.
- Biotechnology – bluebird bio operates in the gene therapy sector, positioning it within the biotechnology industry.
- Investment Banking – The acquisition process, including mergers and tender offers, relates to investment banking services.
Financials
- Approximately 936,791 shares – Shares of bluebird bio stock that have been tendered by May 1, 2025.
- $441 billion – Assets under management by Carlyle as of December 31, 2024.
- $9 billion – Assets under management by SK Capital.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| bluebird bio, Inc. | Target Company | Company | A biotechnology firm specializing in gene therapy with FDA-approved therapies. |
| Carlyle | Bidding Company | Company | A global private equity investment firm with diversified operations and substantial assets under management. |
| SK Capital Partners | Bidding Company | Company | A private investment firm focused on the life sciences and specialty chemicals sectors. |
| Beacon Parent Holdings, L.P. | Bidding Company Parent | Company | Part of the structure of the bidding entity engaging in the tender offer. |
| Beacon Merger Sub, Inc. | Bidding Company Subsidiary | Company | The subsidiary entity orchestrating the tender offer to acquire bluebird bio shares. |
| Equiniti Trust Company, LLC | Depositary | Company | The firm acting as the depositary for the tender offer. |
| U.S. Securities and Exchange Commission (SEC) | Regulatory Body | Government | The U.S. government agency where related tender offer documents are filed. |